Triamcinolone acetonide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329659

CAS#: 76-25-5 (acetonide)

Description: Triamcinolone acetonide is a synthetic corticosteroid used topically to treat various skin conditions, to relieve the discomfort of mouth sores and intra-articularly by proceduralists to treat various joint conditions. In nasal spray form, it is used to treat allergic rhinitis. It is a more potent derivative of triamcinolone, and is about eight times as potent as prednisone. It is also known under the brand names Kenalog (topical) and Volon A as an injection, to treat allergies, arthritis, eye diseases, intestinal problems, and skin diseases. There are possible risks from an injection. It has been known to cause fat and muscle loss at an injection site, leaving a large divot bone deep. In 2014, the FDA made triamcinolone acetonide an over-the-counter drug in the United States in nasal spray form under the brand name Nasacort.

Chemical Structure

Triamcinolone acetonide
CAS# 76-25-5 (acetonide)

Theoretical Analysis

MedKoo Cat#: 329659
Name: Triamcinolone acetonide
CAS#: 76-25-5 (acetonide)
Chemical Formula: C24H31FO6
Exact Mass: 434.21
Molecular Weight: 434.504
Elemental Analysis: C, 66.34; H, 7.19; F, 4.37; O, 22.09

Price and Availability

Size Price Availability Quantity
100mg USD 250
200mg USD 450
500mg USD 650
1g USD 950
2g USD 1450
Bulk inquiry

Related CAS #: 76-25-5 (acetonide), 124-94-7 (free), 67-78-7 (diacetate), 5611-51-8 (hexacetonide)

Synonym: Triamcinolone acetonide; Kenalone; Nasacort; Acetospan; Adcortyl A; AllerNaze; Aristocort. Aristocort A. Aristocort acetonide. Aristoderm. Aristogel.

IUPAC/Chemical Name: (6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-6b-fluoro-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one


InChi Code: InChI=1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h7-9,15-17,19,26,28H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1

SMILES Code: C[C@@]12[C@@]3(C(CO)=O)[C@H](OC(C)(O3)C)C[C@@]1([H])[C@]4([H])CCC5=CC(C=C[C@]5(C)[C@@]4(F)[C@@H](O)C2)=O

Appearance: White to off-white crystalline powder.

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Product Data:

Preparing Stock Solutions

The following data is based on the product molecular weight 434.504400000000000000000000000000 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Jin E, Luo L, Bai Y, Zhao M. Comparative effectiveness of intravitreal bevacizumab with or without triamcinolone acetonide for treatment of diabetic macular edema. Ann Pharmacother. 2015 Apr;49(4):387-97. doi: 10.1177/1060028014568006. Epub 2015 Jan 26. Review. PubMed PMID: 25622852. 2: Ciulla TA, Harris A, McIntyre N, Jonescu-Cuypers C. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Expert Opin Pharmacother. 2014 May;15(7):953-9. doi: 10.1517/14656566.2014.896899. Epub 2014 Mar 24. Review. PubMed PMID: 24661081. 3: Kassim JM, Shipman AR, Szczecinska W, Siah TW, Lam M, Chalmers J, Macbeth AE. How effective is intralesional injection of triamcinolone acetonide compared with topical treatments in inducing and maintaining hair growth in patients with alopecia areata? A Critically Appraised Topic. Br J Dermatol. 2014 Apr;170(4):766-71. doi: 10.1111/bjd.12863. Review. PubMed PMID: 24484438. 4: Jin ZY, Zhu D, Tao Y, Wong IY, Jonas JB. Meta-analysis of the effect of intravitreal bevacizumab versus intravitreal triamcinolone acetonide in central retinal vein occlusion. J Ocul Pharmacol Ther. 2013 Nov;29(9):826-31. doi: 10.1089/jop.2013.0061. Epub 2013 Aug 24. Review. PubMed PMID: 23971622. 5: Athanasiadis Y, Tsatsos M, Sharma A, Hossain P. Subconjunctival triamcinolone acetonide in the management of ocular inflammatory disease. J Ocul Pharmacol Ther. 2013 Jul-Aug;29(6):516-22. doi: 10.1089/jop.2012.0208. Epub 2013 Mar 13. Review. PubMed PMID: 23485045. 6: Fredman R, Tenenhaus M. Cushing's syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey. Burns. 2013 Jun;39(4):549-57. doi: 10.1016/j.burns.2012.09.020. Epub 2012 Oct 23. Review. PubMed PMID: 23092701. 7: Haque MN, Basu S, Padhi TR, Kesarwani S. Acute idiopathic frosted branch angiitis in an 11-month-old infant treated with intravitreal triamcinolone acetonide. J AAPOS. 2012 Oct;16(5):487-8. doi: 10.1016/j.jaapos.2012.06.002. Review. PubMed PMID: 23084392. 8: Qi HP, Bi S, Wei SQ, Cui H, Zhao JB. Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema: a systematic review and meta-analysis. Curr Eye Res. 2012 Dec;37(12):1136-47. doi: 10.3109/02713683.2012.705412. Epub 2012 Jul 13. Review. PubMed PMID: 22793880. 9: Abu-Mugheisib M, Benecke R, Zettl UK. Management of spasticity in progressive multiple sclerosis: efficacy of repeated intrathecal triamcinolone acetonide administration. Curr Pharm Des. 2012;18(29):4564-9. Review. PubMed PMID: 22612755. 10: Veritti D, Di Giulio A, Sarao V, Lanzetta P. Drug safety evaluation of intravitreal triamcinolone acetonide. Expert Opin Drug Saf. 2012 Mar;11(2):331-40. doi: 10.1517/14740338.2012.635141. Epub 2011 Nov 9. Review. PubMed PMID: 22066820. 11: Yilmaz T, Cordero-Coma M, Federici TJ. Pharmacokinetics of triamcinolone acetonide for the treatment of macular edema. Expert Opin Drug Metab Toxicol. 2011 Oct;7(10):1327-35. doi: 10.1517/17425255.2011.606215. Epub 2011 Jul 27. Review. PubMed PMID: 21790508. 12: Becerra EM, Morescalchi F, Gandolfo F, Danzi P, Nascimbeni G, Arcidiacono B, Semeraro F. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr Drug Targets. 2011 Feb;12(2):149-72. Review. PubMed PMID: 20887246. 13: Yilmaz T, Weaver CD, Gallagher MJ, Cordero-Coma M, Cervantes-Castaneda RA, Klisovic D, Lavaque AJ, Larson RJ. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology. 2009 May;116(5):902-11; quiz 912-3. doi: 10.1016/j.ophtha.2009.02.002. Review. PubMed PMID: 19410949. 14: Mansoor S, Kuppermann BD, Kenney MC. Intraocular sustained-release delivery systems for triamcinolone acetonide. Pharm Res. 2009 Apr;26(4):770-84. doi: 10.1007/s11095-008-9812-z. Epub 2009 Jan 28. Review. PubMed PMID: 19184374. 15: Picado C, Vennera Mdel C. [Triamcinolone acetonide in the treatment of corticosteroid-resistant asthma: risks and benefits]. Arch Bronconeumol. 2008 Jun;44(6):324-7. Review. Spanish. PubMed PMID: 18559222. 16: Hochman B, Locali RF, Matsuoka PK, Ferreira LM. Intralesional triamcinolone acetonide for keloid treatment: a systematic review. Aesthetic Plast Surg. 2008 Jul;32(4):705-9. doi: 10.1007/s00266-008-9152-8. Epub 2008 Apr 17. Review. PubMed PMID: 18418647. 17: Van Rijswijk JB, Mylanus EA. Intralesional triamcinolone acetonide injection in hypertrophic skin surrounding the percutaneous titanium implant of a bone-anchored hearing aid. J Laryngol Otol. 2008 Dec;122(12):1368-70. doi: 10.1017/S0022215107001673. Epub 2008 Feb 5. Review. PubMed PMID: 18252013. 18: Gopal L, Sharma T. Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration. Indian J Ophthalmol. 2007 Nov-Dec;55(6):431-5. Review. PubMed PMID: 17951899; PubMed Central PMCID: PMC2635983. 19: Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 2007 Sep-Oct;52(5):503-22. Review. PubMed PMID: 17719372. 20: Jonas JB, Schlichtenbrede F. Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases. Eye (Lond). 2008 Jul;22(7):869-73. Epub 2007 Feb 16. Review. PubMed PMID: 17304257.